Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.

Mamand S, Allchin RL, Ahearne MJ, Wagner SD.

Sci Rep. 2018 Sep 21;8(1):14216. doi: 10.1038/s41598-018-32634-5.

2.

Clonal evolution in the transition from cutaneous disease to acute leukemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm.

Ladikou E, Ottolini B, Nawaz N, Allchin RL, Payne D, Ali H, Marafioti T, Shaw J, Ahearne MJ, Wagner SD.

Haematologica. 2018 May;103(5):e196-e199. doi: 10.3324/haematol.2017.171876. Epub 2018 Feb 1. No abstract available.

3.

Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.

Beck D, Zobel J, Barber R, Evans S, Lezina L, Allchin RL, Blades M, Elliott R, Lord CJ, Ashworth A, Porter AC, Wagner SD.

J Biol Chem. 2016 Aug 5;291(32):16686-98. doi: 10.1074/jbc.M116.736868. Epub 2016 Jun 6.

4.

Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment.

Ahearne MJ, Allchin RL, Fox CP, Wagner SD.

Br J Haematol. 2014 Aug;166(3):326-35. doi: 10.1111/bjh.12941. Epub 2014 May 12. Review.

PMID:
24815671

Supplemental Content

Loading ...
Support Center